[Conservative treatment of placenta accreta].
OBJECTIVE
Examination of modalities and results of conservative treatment of placenta accreta.


METHODS
Ten-year hospital records were reviewed, with analysis of patients who had diagnosis of placenta accreta associated with conservative treatment.


RESULTS
During the study period, 21259 deliveries were registered, with an incidence of placenta accreta of 1 per 1 000 deliveries (n=23). Conservative treatment was applied in 13 patients. All of them had factors commonly associated with placenta accreta: prior cesarean sections (7/13), prior curettage or endouterine surgery (11/13), placenta praevia (11/13). Antenatal diagnosis was performed in only 64% of the cases (n=7). In our conservative strategy, placenta accreta was always left in situ, with an associated treatment in most of cases (n=10): Bilateral hypogastric artery ligation (n=7), medical treatment with methotrexate (n=5), uterine artery embolization (n=2). There was no case of maternal mortality. Conservative treatment was successful in 11 patients. It failed in 2 cases: hysterectomy was performed in one case for life-threatening hemorrhage, and in the other case for post-embolization uterine necrosis. The morbidity described was blood transfusion (n=7), endometritis (n=1), and one late hemorrhage with expelling necrotic tissue. Afterwards, 2 women became pregnant: one miscarriage and one normal term delivery.


CONCLUSIONS
Conservative treatment of placenta accreta appears to be a efficient way to preserve fertility. Antepartum diagnosis should be improved among patients with a high risk of placenta accreta in order to optimize conservative strategy.
Courbière
B
B
Service de Gynécologie-Obstétrique, CHU La Conception, 147, boulevard Baille, 13385 Marseille Cedex.
Bretelle
F
F
Porcu
G
G
Gamerre
M
M
Blanc
B
B
D000020:Abortifacient Agents, Nonsteroidal / Q000627:therapeutic use; D000328:Adult; D001158:Arteries / Q000601:surgery; D004621:Embolization, Therapeutic; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007044:Hysterectomy; D015994:Incidence; D008026:Ligation / Q000379:methods; D008727:Methotrexate / Q000627:therapeutic use; D010921:Placenta Accreta / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D006473:Postpartum Hemorrhage / Q000517:prevention & control; D011247:Pregnancy; D012189:Retrospective Studies; D013270:Stomach / Q000098:blood supply; D016896:Treatment Outcome; D014599:Uterus / Q000098:blood supply
D000020:Abortifacient Agents, Nonsteroidal; D008727:Methotrexate